The Triggering Receptor Expressed On Myeloid Cells 2 pipeline drugs market research report outlays comprehensive information on the Triggering Receptor Expressed On Myeloid Cells 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Triggering Receptor Expressed On Myeloid Cells 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Central Nervous System, Oncology, Immunology, and Metabolic Disorders which include the indications Alzheimer’s Disease, Neurodegenerative Diseases, Solid Tumor, Unspecified Immunological Disorders, Inflammation, and Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)). It also reviews key players involved in Triggering Receptor Expressed On Myeloid Cells 2 targeted therapeutics development with respective active and dormant or discontinued products.

The Triggering Receptor Expressed On Myeloid Cells 2 pipeline targets constitutes close to 11 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 1, 5, and 2 respectively.

Triggering Receptor Expressed On Myeloid Cells 2 overview

Triggering receptor expressed on myeloid cells 2 (TREM2) acts as a receptor for lipoprotein particles such as LDL, VLDL, and HDL and for apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4, and CLU and enhances their uptake in microglia. TREM2 forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding. It acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia.

For a complete picture of Triggering Receptor Expressed On Myeloid Cells 2’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.